Miriam Komaromy MD
Professor, General Internal Medicine
801 Massachusetts Ave | (617) 638-6729
General Internal Medicine
Miriam Komaromy, MD is the Medical Director of the Grayken Center for Addiction at Boston Medical Center, and a Professor in the Division of General Internal Medicine, Department of Medicine, Chobanian and Avedisian School of Medicine. In her role at the Grayken Center she leads programs focused on expanding access to care and engagement with care for patients who have substance use disorders, particularly those from marginalized patient populations. Other areas of focus within the Grayken Center include:
--Development of a new Grayken Addiction Nursing Fellowship and support for the Grayken Addiction Medicine Fellowships
--Leadership on adaptation of SUD treatment during the COVID pandemic, including BMC's COVID Recuperation Unit for people who are COVID-infected and experiencing homelessness
--Research focused on care of young adults with substance use disorder and on care of BIPOC populations
--Policy and Advocacy focused on workforce development, harm reduction, HIV prevention, and overdose prevention in newly housed individuals
Komaromy is also PI of a NIMH-funded clinical trial (along with mPI Dr. Kate Watkins of RAND corporation) that is evaluating the impact of the Collaborative Care model on outcomes of care for people who have co-occurring opioid use disorder plus PTSD or depression in 13 primary care clinics in New Mexico.
Prior to her role at BMC, Komaromy led the Extension for Healthcare Outcomes (ECHO) Institute’s programs for addiction and psychiatry. She has also served on the American Society of Addiction Medicine’s (ASAM’s) National Board of Directors (2017-2021) and served as medical director for a state addiction treatment hospital in New Mexico and for Albuquerque Health Care for the Homeless.
Komaromy recently partnered with the American Society of Addiction Medicine to launch an ECHO hub to educate health care professionals around the country on the treatment of substance use disorders. She also led the federally-funded program that developed and launched five national ECHO hubs focused on treatment of opioid use disorder (including one based in BMC's OBAT program), after developing the nation’s first addiction-focused ECHO program.
Komaromy was previously a professor in the Department of Internal Medicine at the University of New Mexico. She received her medical degree from the University of California, San Francisco and completed her residency in internal medicine at UCSF/San Francisco General Hospital. She was a Robert Wood Johnson Clinical Scholar at the UCSF/Stanford program. She joined the UCSF faculty of Medicine after her training, and served as the residency director for the UCSF Primary Care Internal Medicine Residency program at San Francisco General Hospital. She is board certified in Addiction Medicine by the American Board of Preventive Medicine.
Komaromy’s research has focused on health disparities and care for traditionally underserved populations; models of post-graduate medical education; and care for patients with substance use disorders and complex health conditions. In 2018, Komaromy received a Fulbright Scholar award from the US State Department, teaching about substance use disorders and medical education in Vietnam, Thailand, and Indonesia and studying treatment of opioid use disorder in Vietnam. She is the vice-chair of the ASAM National Medical Education Committee. In 2019 she received ASAM's Educator of the Year award.
Grayken Center for Addiction at BMC
Medicine, MD, University of California, San Francisco, 1989
Philosophy & Classical Studies, BA, St. John's College, 1983
Murray-Krezan C, Dopp A, Tarhuni L, Carmody MD, Becker K, Anderson J, Komaromy M, Meredith LS, Watkins KE, Wagner K, Page K. Screening for opioid use disorder and co-occurring depression and post-traumatic stress disorder in primary care in New Mexico. Addict Sci Clin Pract. 2023 Jan 27; 18(1):6. PMID: 36707910.Published on 4/8/2022
Osilla KC, Dopp AR, Watkins KE, Ceballos V, Hurley B, Meredith LS, Leamon I, Jacobsohn V, Komaromy M. Collaboration Leading to Addiction Treatment and Recovery from Other Stresses (CLARO): process of adapting collaborative care for co-occurring opioid use and mental disorders. Addict Sci Clin Pract. 2022 Apr 08; 17(1):25. PMID: 35395811.Published on 3/26/2022
Qeadan F, Madden EF, Barbeau WA, Kroth PJ, Porucznik CA, English K, Komaromy M, Sulzer SH. Characteristics associated with the availability of therapeutic acupuncture in substance use disorder treatment facilities in the United States. J Addict Dis. 2023 Jan-Mar; 41(1):41-52. PMID: 35343390.Published on 12/28/2021
Laks J, Kehoe J, Farrell NM, Komaromy M, Kolodziej J, Walley AY, Taylor JL. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule. Addict Sci Clin Pract. 2021 12 28; 16(1):73. PMID: 34961554.Published on 11/1/2021
Komaromy M, Tomanovich M, Taylor JL, Ruiz-Mercado G, Kimmel SD, Bagley SM, Saia KM, Costello E, Park TW, LaBelle C, Weinstein Z, Walley AY. Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic. J Addict Med. 2021 Nov-Dec 01; 15(6):448-451. PMID: 33298750.Published on 10/26/2021
Qeadan F, Azagba S, Barbeau WA, Gu LY, Mensah NA, Komaromy M, English K, Madden EF. Associations between discrimination and substance use among college students in the United States from 2015 to 2019. Addict Behav. 2022 02; 125:107164. PMID: 34735979.Published on 7/16/2021
Harris MTH, Young S, Barocas J, Bayoumi AM, Caudarella A, Laurence G, Tomanovich M, Komaromy M. A Descriptive Comparison of Substance Use Services in Recovery and Isolation Sites for People Experiencing Homelessness During the COVID-19 Pandemic, Boston and Toronto. Public Health Rep. 2021 Sep-Oct; 136(5):532-537. PMID: 34269625.Published on 3/10/2021
Meredith LS, Komaromy MS, Cefalu M, Murray-Krezan C, Page K, Osilla KC, Dopp AR, Leamon I, Tarhuni L, Hindmarch G, Jacobsohn V, Watkins KE. Design of CLARO (Collaboration Leading to Addiction Treatment and Recovery from other Stresses): A randomized trial of collaborative care for opioid use disorder and co-occurring depression and/or posttraumatic stress disorder. Contemp Clin Trials. 2021 05; 104:106354. PMID: 33713840.Published on 3/1/2021
Barocas JA, Gai MJ, White LF, Faretra D, Sachs K, Komaromy M. Implementation of a Recuperation Unit and Hospitalization Rates Among People Experiencing Homelessness With COVID-19. JAMA Netw Open. 2021 03 01; 4(3):e212826. PMID: 33688963.Published on 1/19/2021
Komaromy M, Harris M, Koenig RM, Tomanovich M, Ruiz-Mercado G, Barocas JA. Caring for COVID's Most Vulnerable Victims: a Safety-Net Hospital Responds. J Gen Intern Med. 2021 04; 36(4):1006-1010. PMID: 33469746.
Published on 5/17/2023
U.S. Will Fund Study of Safe Injection Sites Despite Pushback
Published on 5/11/2023
The COVID emergency is expiring in Massachusetts. What happens now?
Published on 5/11/2023
How Can We Make Addiction Care More Appealing and Effective for Black Patients?
Published on 2/2/2023
Safe Injection Sites Have Gained a Foothold in the U.S. Are More on the Way?
Published on 2/2/2023
The COVID-19 public health emergency ends May 11. What happens then?
Published on 2/1/2023
The national COVID-19 public health emergency will end in May but some of its provisions may survive in Mass.
Published on 1/10/2023
Dry January can kick-start healthy habits that last beyond the month, experts say
Published on 12/14/2022
Consuming alcohol responsibly and supporting people with addiction during the holidays
Published on 9/27/2022
‘Making overdose crisis more severe’: Concerns over animal tranquilizer growing in Massachusetts
Published on 8/29/2022
20,000 flags planted on Boston Common to remember lives lost to drug overdosesView full list of 56 media mentions.